ALK and non-small cell lung carcinoma: Similarly, the EML4-ALK fusion, which is prevalent in 3–5% of patients with non-small cell lung cancer (NSCLC), is a target for tyrosine kinase inhibitors, and the fusion targeting therapy improved the prognosis of these patients significantly [3,4].